These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 10668104)

  • 1. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices.
    Stepień A; Chalimoniuk M; Strosznajder J
    Cephalalgia; 1999 Dec; 19(10):859-65. PubMed ID: 10668104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of serotonergic 5-HT1A receptor reduces Ca(2+)- and glutamatergic receptor-evoked arachidonic acid and No/cGMP release in adult hippocampus.
    Strosznajder J; Chalimoniuk M; Samochocki M
    Neurochem Int; 1996 Apr; 28(4):439-44. PubMed ID: 8740452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat.
    Storer RJ; Goadsby PJ
    Brain; 1997 Dec; 120 ( Pt 12)():2171-7. PubMed ID: 9448572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide-evoked glutamate release and cGMP production in cerebellar slices: control by presynaptic 5-HT1D receptors.
    Marcoli M; Cervetto C; Paluzzi P; Guarnieri S; Raiteri M; Maura G
    Neurochem Int; 2006 Jul; 49(1):12-9. PubMed ID: 16469416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro.
    Maura G; Raiteri M
    J Neurochem; 1996 Jan; 66(1):203-9. PubMed ID: 8522955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
    Hoskin KL; Goadsby PJ
    Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum. Effects of amyloid beta peptide.
    Chalimoniuk M; Strosznajder JB
    Mol Chem Neuropathol; 1998; 35(1-3):77-95. PubMed ID: 10343972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain.
    Johnson DE; Rollema H; Schmidt AW; McHarg AD
    Eur J Pharmacol; 2001 Aug; 425(3):203-10. PubMed ID: 11513839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central sites of actions of zolmitriptan and sumatriptan: 5HT1B, 5HT1D and 5HT1F receptor distribution.
    Pascual J; Castro ME; Pazos A
    Cephalalgia; 1997 Oct; 17(6):711. PubMed ID: 9350394
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
    Proietti-Cecchini A; Afra J; Schoenen J
    Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMDA receptor-dependent nitric oxide and cGMP synthesis in brain hemispheres and cerebellum during reperfusion after transient forebrain ischemia in gerbils: effect of 7-Nitroindazole.
    Chalimoniuk M; Strosznajder J
    J Neurosci Res; 1998 Dec; 54(5):681-90. PubMed ID: 9843159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
    Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
    Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sumatriptan on coronary flow and left ventricular function in the isolated perfused guinea pig heart.
    Le Grand B; Vié B; John GW
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):435-42. PubMed ID: 9733357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptans attenuate circadian responses to light.
    Basu P; Ie N; Wensel AL; Baskerville JD; Smith VM; Antle MC
    Eur J Neurosci; 2015 Oct; 42(7):2489-95. PubMed ID: 26228801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat.
    Pagniez F; Valentin JP; Vieu S; Colpaert FC; John GW
    Br J Pharmacol; 1998 Jan; 123(2):205-14. PubMed ID: 9489607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide in retina: relation to excitatory amino acids and excitotoxicity.
    Zeevalk GD; Nicklas WJ
    Exp Eye Res; 1994 Mar; 58(3):343-50. PubMed ID: 7513649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Firing characteristics of deep dorsal horn neurons after acute spinal transection during administration of agonists for 5-HT1B/1D and NMDA receptors.
    Thaweerattanasinp T; Heckman CJ; Tysseling VM
    J Neurophysiol; 2016 Oct; 116(4):1644-1653. PubMed ID: 27486104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 5HT in migraine.
    Buzzi MG
    Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptors.
    Maura G; Marcoli M; Pepicelli O; Rosu C; Viola C; Raiteri M
    Br J Pharmacol; 2000 Aug; 130(8):1853-8. PubMed ID: 10952674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
    Whale R; Bhagwagar Z; Cowen PJ
    Psychopharmacology (Berl); 1999 Jul; 145(2):223-6. PubMed ID: 10463324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.